

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

- Novartis Pharmaceuticals Corporation
- Novartis Pharmaceuticals Corporation
- Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

- Novartis Pharmaceuticals Corporation
- Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

- Novartis Pharmaceuticals Corporation 2011 2 28 76 50<sup>10</sup>
- Novartis Pharmaceuticals Corporation 50 19 17 1 1 2 6 14 1 11 2011 2 28<sup>10</sup>
- Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

- Novartis Pharmaceuticals Corporation S1P1<sup>20</sup>
- Novartis Pharmaceuticals Corporation
- Novartis Pharmaceuticals Corporation<sup>30</sup>
- Novartis Pharmaceuticals Corporation<sup>40</sup>
- Novartis Pharmaceuticals Corporation F1<sup>50</sup>

1 23 8 9 3. iii. 4  
2 Allende ML, Proia RL Biochim Biophys Acta 1582 1-3 222-227, 2002  
3 CTD2.6.6-6.2  
4 CTD2.6.6-6.4  
5 CTD2.6.6-6.5

- 

- 

CTD2.4-4.2

- 
- 
- 
- 

**Q**

**A**

6 9 2